SG Americas Securities LLC boosted its holdings in AstraZeneca plc (NYSE:AZN) by 7.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 135,398 shares of the company’s stock after purchasing an additional 9,686 shares during the quarter. SG Americas Securities LLC’s holdings in AstraZeneca were worth $6,035,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in AZN. Cedar Brook Financial Partners LLC grew its holdings in shares of AstraZeneca by 3.9% during the second quarter. Cedar Brook Financial Partners LLC now owns 6,916 shares of the company’s stock valued at $285,000 after buying an additional 258 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its holdings in AstraZeneca by 37.6% in the second quarter. San Francisco Sentry Investment Group CA now owns 967 shares of the company’s stock worth $40,000 after purchasing an additional 264 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in AstraZeneca by 1.3% in the third quarter. Steward Partners Investment Advisory LLC now owns 20,651 shares of the company’s stock worth $920,000 after purchasing an additional 275 shares during the last quarter. Doyle Wealth Management boosted its holdings in AstraZeneca by 0.9% in the second quarter. Doyle Wealth Management now owns 32,105 shares of the company’s stock worth $1,325,000 after purchasing an additional 278 shares during the last quarter. Finally, Icon Wealth Partners LLC boosted its holdings in AstraZeneca by 6.0% in the second quarter. Icon Wealth Partners LLC now owns 4,990 shares of the company’s stock worth $206,000 after purchasing an additional 281 shares during the last quarter. Institutional investors and hedge funds own 17.54% of the company’s stock.
Several brokerages recently issued reports on AZN. Deutsche Bank restated a “buy” rating on shares of AstraZeneca in a report on Friday, October 25th. Liberum Capital upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Friday, October 25th. ValuEngine cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Goldman Sachs Group restated a “sell” rating on shares of AstraZeneca in a report on Thursday, October 24th. Finally, Argus raised their target price on shares of AstraZeneca to $50.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $46.53.
In other news, major shareholder Plc Astrazeneca acquired 425,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average cost of $19.00 per share, for a total transaction of $8,075,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
AZN traded up $0.46 during trading on Friday, hitting $47.26. The company’s stock had a trading volume of 5,329,322 shares, compared to its average volume of 4,158,044. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 1.29. AstraZeneca plc has a one year low of $35.30 and a one year high of $49.22. The firm has a market cap of $122.79 billion, a PE ratio of 27.32, a P/E/G ratio of 1.53 and a beta of 0.48. The business’s 50 day simple moving average is $45.32 and its 200-day simple moving average is $42.22.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $0.05. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business had revenue of $6.13 billion for the quarter, compared to the consensus estimate of $6.07 billion. During the same period last year, the firm earned $0.71 earnings per share. The company’s quarterly revenue was up 14.8% on a year-over-year basis. Equities research analysts expect that AstraZeneca plc will post 1.81 EPS for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Diversification Important in Investing
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.